We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

COVID-19 Vaccine Developers to Issue Joint Public Pledge Against Premature Launch Before Proving Safety and Effectiveness

By HospiMedica International staff writers
Posted on 07 Sep 2020
Several developers of COVID-19 vaccines are coming together to issue a public pledge against seeking government approval until their candidates prove to be safe and effective, in a move to reassure the public that they will not compromise scientific, regulatory rigor amidst the urgency to develop a coronavirus vaccine.

According to a report by The Wall Street Journal (WSJ), vaccine makers including Pfizer Inc. (New York, NY, USA), Johnson & Johnson (New Brunswick, NJ, USA) and Moderna, Inc. (Cambridge, MA, USA) are finalizing the draft of the joint statement that commits to making the safety and well-being of vaccinated people their priority. The companies will also pledge to adhere to high scientific and ethical standards in the conduct of clinical studies and in their manufacturing processes. According to the draft statement, the vaccine makers will submit applications for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) or licensure of vaccines based on “substantial evidence of safety and efficacy” from Phase 3 clinical trials being conducted under the FDA’s guidance.

Illustration
Illustration

“We believe this pledge will help ensure public confidence in the COVID-19 vaccines that may ultimately be approved and adherence to the rigorous scientific and regulatory process by which they are evaluated,” says the draft statement, as mentioned in the WSJ report.

Separately, speaking at an online press briefing organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Pfizer’s Chief Executive Albert Bourla said, “We will never ourselves submit for authorization or approval any vaccine before we feel it is safe and effective. We will not cut corners.”

At the IFPMA event, rival Merck’s Chief Executive Kenneth Frazier also assured that safety remained their top priority and said, “We all understand the need to move with urgency given the pandemic, but we will not sacrifice safety under any set of circumstances.”

Related Links:
Pfizer Inc.
Johnson & Johnson
Moderna, Inc.



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Computed Tomography System
Aquilion ONE / INSIGHT Edition
New
Mini C-arm Imaging System
Fluoroscan InSight FD

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles